Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.
Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki 00014, Finland.
Hum Mol Genet. 2023 Jun 5;32(12):2103-2116. doi: 10.1093/hmg/ddad043.
Genome-wide association studies (GWAS) have successfully identified associations for cervical cancer, but the underlying mechanisms of cervical biology and pathology remain uncharacterised. Our GWAS meta-analyses fill this gap, as we characterise the genetic architecture of cervical phenotypes, including cervical ectropion, cervicitis, cervical dysplasia, as well as up to 9229 cases and 490 304 controls for cervical cancer from diverse ancestries. Leveraging the latest computational methods and gene expression data, we refine the association signals for cervical cancer and propose potential causal variants and genes at each locus. We prioritise PAX8/PAX8-AS1, LINC00339, CDC42, CLPTM1L, HLA-DRB1 and GSDMB as the most likely candidate genes for cervical cancer signals, providing insights into cervical cancer pathogenesis and supporting the involvement of reproductive tract development, immune response and cellular proliferation/apoptosis. We construct a genetic risk score (GRS) that is associated with cervical cancer [hazard ratios (HR) = 3.1 (1.7-5.6) for the top 15% vs lowest 15% of individuals], and with other HPV- and immune-system-related diagnoses in a phenome-wide association study analysis. Our results propose valuable leads for further functional studies and present a GRS for cervical cancer that allows additional risk stratification and could potentially be used to personalise the conventional screening strategies for groups more susceptible to cervical cancer.
全基因组关联研究 (GWAS) 已成功鉴定出与宫颈癌相关的关联,但宫颈癌的生物学和病理学的潜在机制仍未被阐明。我们的 GWAS 荟萃分析填补了这一空白,因为我们描述了宫颈表型的遗传结构,包括宫颈外翻、宫颈炎、宫颈发育不良,以及来自不同种族的 9229 例宫颈癌病例和 490304 例对照。利用最新的计算方法和基因表达数据,我们对宫颈癌的关联信号进行了精细化分析,并提出了每个位点的潜在因果变异和基因。我们将 PAX8/PAX8-AS1、LINC00339、CDC42、CLPTM1L、HLA-DRB1 和 GSDMB 优先视为宫颈癌信号的最可能候选基因,为宫颈癌发病机制提供了新的见解,并支持生殖道发育、免疫反应和细胞增殖/凋亡的参与。我们构建了一个与宫颈癌相关的遗传风险评分 (GRS) [最高 15%与最低 15%个体的危险比 (HR)为 3.1(1.7-5.6)],并在表型全基因组关联研究分析中与其他 HPV 和免疫系统相关的诊断相关。我们的研究结果为进一步的功能研究提供了有价值的线索,并提出了一种用于宫颈癌的 GRS,允许进一步的风险分层,并可能用于为更容易患宫颈癌的群体定制常规筛查策略。